Literature DB >> 1322235

Early and multifocal tumors in breast, salivary, harderian and epididymal tissues developed in MMTY-Neu transgenic mice.

F Lucchini1, M G Sacco, N Hu, A Villa, J Brown, L Cesano, L Mangiarini, G Rindi, S Kindl, F Sessa.   

Abstract

Transgenic mice carrying various oncogenes driven by mammary gland specific enhancers develop mammary tumors usually arising in a stochastic way. The only exception is a mouse lineage (TG.NF) carrying an activated rat Neu oncogene driven by the murine mammary tumor virus long terminal repeat (MMTV-LTR) that gave rise to rapid and multifocal mammary tumors interpreted as a result of a single-step neoplastic transformation. The effect of the oncogene appeared to be specific for breast tissue, since salivary and Harderian glands as well as epididymis expressed high levels of Neu but only developed hyperplasia (Muller et al., Cell, (1988) 54, p. 105). Here we describe a transgenic mouse lineage for the MMTV-Neu, analysed up to third generation. Multifocal tumors involving mammary glands arose very rapidly in all females independently from pregnancy and in some males. Moreover, multifocal neoplasias occurred also in salivary and Harderian glands and in the epididymis at a very high rate. These data demonstrate that the Neu oncogene can induce tumors in all the tissues where it is expressed at high levels.

Entities:  

Mesh:

Year:  1992        PMID: 1322235     DOI: 10.1016/0304-3835(92)90044-v

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  34 in total

1.  Oncogene-driven intrinsic inflammation induces leukocyte production of tumor necrosis factor that critically contributes to mammary carcinogenesis.

Authors:  Sabina Sangaletti; Claudio Tripodo; Chiara Ratti; Silvia Piconese; Rossana Porcasi; Rosalba Salcedo; Giorgio Trinchieri; Mario P Colombo; Claudia Chiodoni
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

2.  Porous silicon microparticle potentiates anti-tumor immunity by enhancing cross-presentation and inducing type I interferon response.

Authors:  Xiaojun Xia; Junhua Mai; Rong Xu; Jorge Enrique Tovar Perez; Maria L Guevara; Qi Shen; Chaofeng Mu; Hui-Ying Tung; David B Corry; Scott E Evans; Xuewu Liu; Mauro Ferrari; Zhiqiang Zhang; Xian Chang Li; Rong-Fu Wang; Haifa Shen
Journal:  Cell Rep       Date:  2015-04-30       Impact factor: 9.423

3.  The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.

Authors:  Tamara Utermark; Trisha Rao; Hailing Cheng; Qi Wang; Sang Hyun Lee; Zhigang C Wang; J Dirk Iglehart; Thomas M Roberts; William J Muller; Jean J Zhao
Journal:  Genes Dev       Date:  2012-07-15       Impact factor: 11.361

4.  Development of hyperplasias, preneoplasias, and mammary tumors in MMTV-c-erbB-2 and MMTV-TGFalpha transgenic rats.

Authors:  B R Davies; A M Platt-Higgins; G Schmidt; P S Rudland
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

5.  Cryotherapy with concurrent CpG oligonucleotide treatment controls local tumor recurrence and modulates HER2/neu immunity.

Authors:  Jesse J Veenstra; Heather M Gibson; Peter J Littrup; Joyce D Reyes; Michael L Cher; Akira Takashima; Wei-Zen Wei
Journal:  Cancer Res       Date:  2014-08-04       Impact factor: 12.701

Review 6.  Genetically modified laboratory mice with sebaceous glands abnormalities.

Authors:  Carmen Ehrmann; Marlon R Schneider
Journal:  Cell Mol Life Sci       Date:  2016-07-25       Impact factor: 9.261

7.  In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells.

Authors:  Deepak Assudani; Hyun-Il Cho; Nicholas DeVito; Norma Bradley; Esteban Celis
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

8.  Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors.

Authors:  Pilar Nava-Parada; Guido Forni; Keith L Knutson; Larry R Pease; Esteban Celis
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

9.  Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity.

Authors:  Jennifer B Jacob; Yi-chi M Kong; Ilke Nalbantoglu; Daniel P Snower; Wei-Zen Wei
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

10.  Immunogenicity and therapeutic efficacy of a dual-component genetic cancer vaccine cotargeting carcinoembryonic antigen and HER2/neu in preclinical models.

Authors:  Luigi Aurisicchio; Daniela Peruzzi; Gloria Koo; Wei-Zen Wei; Nicola La Monica; Gennaro Ciliberto
Journal:  Hum Gene Ther       Date:  2013-12-21       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.